In GBM, TERTp mutations coexist with EGFR amplification [64,77,111], and in urothelial bladder carcinoma, they are associated with FGFR3 (Fibroblast Growth Factor Receptor 3) mutations [61,94]. This evidence concerns the gene EGFR and glioblastoma.